Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 75
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Cell Rep ; 37(7): 110006, 2021 11 16.
Artículo en Inglés | MEDLINE | ID: mdl-34788614

RESUMEN

Secretory immunoglobulin A (SIgA) can travel to and from the lumen and transport antigen to subepithelial cells. However, IgM can also multimerize into functional secretory component-bound immunoglobulin. While it is already known that both SIgA and SIgM undergo transcytosis to be secreted at the mucosal surface, only SIgA has been shown to perform retrotranscytosis through microfold cells (M cells) of the Peyer's patch. Here, we investigate whether SIgM could also be taken up by M cells via retrotranscytosis. This transport involves FcµR binding at the apical membrane of M cells. We then demonstrate that SIgM can be exploited by SIgM-p24 (HIV-capsid protein) complexes during immunization in the nasal- or gut-associated lymphoid tissue (NALT or GALT), conferring efficient immune responses against p24. Our data demonstrate a mucosal function of SIgM, which could play a role in the regulation of mucosal immunity.


Asunto(s)
Proteínas Reguladoras de la Apoptosis/metabolismo , Intestinos/fisiología , Proteínas de la Membrana/metabolismo , Transcitosis/fisiología , Animales , Proteínas Reguladoras de la Apoptosis/fisiología , Femenino , Inmunidad Mucosa/fisiología , Inmunoglobulina A Secretora/metabolismo , Inmunoglobulina M/inmunología , Mucosa Intestinal/metabolismo , Intestinos/inmunología , Intestinos/metabolismo , Proteínas de la Membrana/fisiología , Ratones , Ratones Endogámicos BALB C , Ganglios Linfáticos Agregados/citología , Transcitosis/genética
2.
Nat Commun ; 12(1): 261, 2021 01 11.
Artículo en Inglés | MEDLINE | ID: mdl-33431850

RESUMEN

Intestinal microfold cells are the primary pathway for translocation of secretory IgA (SIgA)-pathogen complexes to gut-associated lymphoid tissue. Uptake of SIgA/commensals complexes is important for priming adaptive immunity in the mucosa. This study aims to explore the effect of SIgA retrograde transport of immune complexes in Crohn's disease (CD). Here we report a significant increase of SIgA transport in CD patients with NOD2-mutation compared to CD patients without NOD2 mutation and/or healthy individuals. NOD2 has an effect in the IgA transport through human and mouse M cells by downregulating Dectin-1 and Siglec-5 expression, two receptors involved in retrograde transport. These findings define a mechanism of NOD2-mediated regulation of mucosal responses to intestinal microbiota, which is involved in CD intestinal inflammation and dysbiosis.


Asunto(s)
Enfermedad de Crohn/metabolismo , Inmunoglobulina A Secretora/metabolismo , Proteína Adaptadora de Señalización NOD2/metabolismo , Animales , Colitis/microbiología , Colitis/patología , Enfermedad de Crohn/patología , Humanos , Lectinas Tipo C/metabolismo , Ratones Noqueados , Modelos Biológicos , Mutación/genética , Proteína Adaptadora de Señalización NOD2/deficiencia , Proteína Adaptadora de Señalización NOD2/genética , Ganglios Linfáticos Agregados/metabolismo , Transporte de Proteínas , Salmonella/fisiología , Lectinas Similares a la Inmunoglobulina de Unión a Ácido Siálico/metabolismo , Transcitosis
3.
Eur J Immunol ; 50(9): 1295-1306, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32277709

RESUMEN

Human IgA could be from different isotypes (IgA1/IgA2) and/or isoforms (monomeric, dimeric, or secretory). Monomeric IgA mainly IgA1 are considered as an anti-inflammatory isotype whereas dimeric/secretory IgA have clearly dual pro- and anti-inflammatory effects. Here, we show that IgA isotypes and isoforms display different binding abilities to FcαRI, Dectin-1, DC-SIGN, and CD71 on monocyte-derived dendritic cells (moDC). We describe that IgA regulate the expression of their own receptors and trigger modulation of moDC maturation. We also demonstrate that dimeric IgA2 and IgA1 induce different inflammatory responses leading to cytotoxic CD8+ T cells activation. moDC stimulation by dimeric IgA2 was followed by a strong pro-inflammatory effect. Our study highlights differences regarding IgA isotypes and isoforms in the context of DC conditioning. Further investigations are needed on the activation of adaptive immunity by IgA in the context of microbiota/IgA complexes during antibody-mediated immune selection.


Asunto(s)
Linfocitos T CD8-positivos/inmunología , Células Dendríticas/inmunología , Inmunoglobulina A/inmunología , Activación de Linfocitos/inmunología , Humanos , Inmunoglobulina A/química , Isoformas de Proteínas
4.
J Virol ; 92(23)2018 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-30232191

RESUMEN

Noroviruses are enteric pathogens causing significant morbidity, mortality, and economic losses worldwide. Secretory immunoglobulins (sIg) are a first line of mucosal defense against enteric pathogens. They are secreted into the intestinal lumen via the polymeric immunoglobulin receptor (pIgR), where they bind to antigens. However, whether natural sIg protect against norovirus infection remains unknown. To determine if natural sIg alter murine norovirus (MNV) pathogenesis, we infected pIgR knockout (KO) mice, which lack sIg in mucosal secretions. Acute MNV infection was significantly reduced in pIgR KO mice compared to controls, despite increased MNV target cells in the Peyer's patch. Natural sIg did not alter MNV binding to the follicle-associated epithelium (FAE) or crossing of the FAE into the lymphoid follicle. Instead, naive pIgR KO mice had enhanced levels of the antiviral inflammatory molecules interferon gamma (IFN-γ) and inducible nitric oxide synthase (iNOS) in the ileum compared to controls. Strikingly, depletion of the intestinal microbiota in pIgR KO and control mice resulted in comparable IFN-γ and iNOS levels, as well as MNV infectious titers. IFN-γ treatment of wild-type (WT) mice and neutralization of IFN-γ in pIgR KO mice modulated MNV titers, implicating the antiviral cytokine in the phenotype. Reduced gastrointestinal infection in pIgR KO mice was also observed with another enteric virus, reovirus. Collectively, our findings suggest that natural sIg are not protective during enteric virus infection, but rather, that sIg promote enteric viral infection through alterations in microbial immune responses.IMPORTANCE Enteric virus, such as norovirus, infections cause significant morbidity and mortality worldwide. However, direct antiviral infection prevention strategies are limited. Blocking host entry and initiation of infection provides an established avenue for intervention. Here, we investigated the role of the polymeric immunoglobulin receptor (pIgR)-secretory immunoglobulin (sIg) cycle during enteric virus infections. The innate immune functions of sIg (agglutination, immune exclusion, neutralization, and expulsion) were not required during control of acute murine norovirus (MNV) infection. Instead, lack of pIgR resulted in increased IFN-γ levels, which contributed to reduced MNV titers. Another enteric virus, reovirus, also showed decreased infection in pIgR KO mice. Collectively, our data point to a model in which sIg-mediated microbial sensing promotes norovirus and reovirus infection. These data provide the first evidence of the proviral role of natural sIg during enteric virus infections and provide another example of how intestinal bacterial communities indirectly influence MNV pathogenesis.


Asunto(s)
Infecciones por Caliciviridae/virología , Tracto Gastrointestinal/virología , Inmunoglobulinas/metabolismo , Receptores de Inmunoglobulina Polimérica/fisiología , Infecciones por Reoviridae/virología , Replicación Viral/inmunología , Animales , Infecciones por Caliciviridae/inmunología , Infecciones por Caliciviridae/metabolismo , Tracto Gastrointestinal/inmunología , Interferón gamma/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Óxido Nítrico Sintasa de Tipo II/metabolismo , Norovirus/inmunología , Reoviridae/inmunología , Infecciones por Reoviridae/inmunología , Infecciones por Reoviridae/metabolismo
5.
Front Immunol ; 9: 431, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29563912

RESUMEN

Vaccination is the process of administering immunogenic formulations in order to induce or harness antigen (Ag)-specific antibody and T cell responses in order to protect against infections. Important successes have been obtained in protecting individuals against many deleterious pathological situations after parenteral vaccination. However, one of the major limitations of the current vaccination strategies is the administration route that may not be optimal for the induction of immunity at the site of pathogen entry, i.e., mucosal surfaces. It is now well documented that immune responses along the genital, respiratory, or gastrointestinal tracts have to be elicited locally to ensure efficient trafficking of effector and memory B and T cells to mucosal tissues. Moreover, needle-free mucosal delivery of vaccines is advantageous in terms of safety, compliance, and ease of administration. However, the quest for mucosal vaccines is challenging due to (1) the fact that Ag sampling has to be performed across the epithelium through a relatively limited number of portals of entry; (2) the deleterious acidic and proteolytic environment of the mucosae that affect the stability, integrity, and retention time of the applied Ags; and (3) the tolerogenic environment of mucosae, which requires the addition of adjuvants to elicit efficient effector immune responses. Until now, only few mucosally applicable vaccine formulations have been developed and successfully tested. In animal models and clinical trials, the use of lipidic structures such as liposomes, virosomes, immune stimulating complexes, gas-filled microbubbles and emulsions has proven efficient for the mucosal delivery of associated Ags and the induction of local and systemic immune reponses. Such particles are suitable for mucosal delivery because they protect the associated payload from degradation and deliver concentrated amounts of Ags via specialized sampling cells (microfold cells) within the mucosal epithelium to underlying antigen-presenting cells. The review aims at summarizing recent development in the field of mucosal vaccination using lipid-based particles. The modularity ensured by tailoring the lipidic design and content of particles, and their known safety as already established in humans, make the continuing appraisal of these vaccine candidates a promising development in the field of targeted mucosal vaccination.


Asunto(s)
Infecciones/inmunología , Membrana Mucosa/inmunología , Vacunación , Vacunas/inmunología , Animales , Sistemas de Liberación de Medicamentos , Humanos , Inmunidad Mucosa , Lípidos , Microburbujas
6.
Artículo en Inglés | MEDLINE | ID: mdl-29423380

RESUMEN

To define the bottlenecks that restrict antigen expression after oral administration of viral-vectored vaccines, we tracked vectors derived from the human adenovirus type 5 at whole body, tissue, and cellular scales throughout the digestive tract in a murine model of oral delivery. After intragastric administration of vectors encoding firefly luciferase or a model antigen, detectable levels of transgene-encoded protein or mRNA were confined to the intestine, and restricted to delimited anatomical zones. Expression of luciferase in the form of multiple small bioluminescent foci in the distal ileum, cecum, and proximal colon suggested multiple crossing points. Many foci were unassociated with visible Peyer's patches, implying that transduced cells lay in proximity to villous rather than follicle-associated epithelium, as supported by detection of transgene-encoded antigen in villous epithelial cells. Transgene-encoded mRNA but not protein was readily detected in Peyer's patches, suggesting that post-transcriptional regulation of viral gene expression might limit expression of transgene-encoded antigen in this tissue. To characterize the pathways by which the vector crossed the intestinal epithelium and encountered sentinel cells, a fluorescent-labeled vector was administered to mice by the intragastric route or inoculated into ligated intestinal loops comprising a Peyer's patch. The vector adhered selectively to microfold cells in the follicle-associated epithelium, and, after translocation to the subepithelial dome region, was captured by phagocytes that expressed CD11c and lysozyme. In conclusion, although a large number of crossing events took place throughout the intestine within and without Peyer's patches, multiple firewalls prevented systemic dissemination of vector and suppressed production of transgene-encoded protein in Peyer's patches.


Asunto(s)
Adenovirus Humanos/genética , Adenovirus Humanos/inmunología , Vectores Genéticos/genética , Vectores Genéticos/inmunología , Transgenes/genética , Transgenes/inmunología , Administración Oral , Animales , Femenino , Expresión Génica , Genes Reporteros , Vectores Genéticos/administración & dosificación , Humanos , Inmunización , Mucosa Intestinal/inmunología , Mucosa Intestinal/metabolismo , Ratones , Especificidad de Órganos , Ganglios Linfáticos Agregados/inmunología , Ganglios Linfáticos Agregados/metabolismo , Fagocitos/metabolismo , Transporte de Proteínas , Vacunación
7.
Front Immunol ; 9: 2970, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30619327

RESUMEN

Secretory immunoglobulins have a critical role in defense of the gastrointestinal tract and are known to act by preventing bacterial acquisition. A stringent murine model of bacterial infection with Salmonella enterica Typhimurium was used to examine protection mediated by oral passive immunization with human plasma-derived polyreactive IgA and IgM antibodies (Abs) reconstituted as secretory-like immunoglobulins (SCIgA/M). This reagent has been shown to trigger Salmonella agglutination and to limit the entry of bacterium into intestinal Peyer's patches via immune exclusion. We now demonstrate that upon administration into ligated intestinal loops, SCIgA/M properly anchors in the mucus and is protected from degradation to a better extent that IgA/M or IgG. Moreover, prophylactic oral administration of SCIgA/M before intragastric infection of mice with a virulent strain of S. enterica Typhimurium allows to protect infected animals, as reflected by reduced colonization of both mucosal and systemic compartments, and conserved integrity of intestinal tissues. In comparison with IgA/M or IgG administration, SCIgA/M provided the highest degree of protection. Moreover, such protective efficacy is also observed after therapeutic oral delivery of SCIgA/M. Either prophylactic or therapeutic treatment with passively delivered SCIgA/M ensured survival of up to 50% of infected mice, while untreated animals all died. Our findings unravel the potential of oral passive immunization with plasma-derived polyreactive SCIgA/M Abs to fight gastrointestinal infections.


Asunto(s)
Inmunización Pasiva/métodos , Inmunoglobulina A Secretora/administración & dosificación , Inmunoglobulina M/administración & dosificación , Infecciones por Salmonella/terapia , Salmonella typhimurium/inmunología , Administración Oral , Animales , Modelos Animales de Enfermedad , Femenino , Humanos , Inmunoglobulina A Secretora/sangre , Inmunoglobulina A Secretora/aislamiento & purificación , Inmunoglobulina M/sangre , Inmunoglobulina M/aislamiento & purificación , Mucosa Intestinal/inmunología , Mucosa Intestinal/microbiología , Ratones , Ratones Endogámicos BALB C , Ganglios Linfáticos Agregados/inmunología , Ganglios Linfáticos Agregados/microbiología , Plasma/inmunología , Infecciones por Salmonella/inmunología , Infecciones por Salmonella/microbiología , Salmonella typhimurium/patogenicidad , Resultado del Tratamiento
8.
Front Immunol ; 8: 1043, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28900429

RESUMEN

Due to the increasing emergence of antibiotic-resistant strains of enteropathogenic bacteria, development of alternative treatments to fight against gut infections is a major health issue. While vaccination requires that a proper combination of antigen, adjuvant, and delivery route is defined to elicit protective immunity at mucosae, oral delivery of directly active antibody preparations, referred to as passive immunization, sounds like a valuable alternative. Along the gut, the strategy suffers, however, from the difficulty to obtain sufficient amounts of antibodies with the appropriate specificity and molecular structure for mucosal delivery. Physiologically, at the antibody level, the protection of gastrointestinal mucosal surfaces against enteropathogens is principally mediated by secretory IgA and secretory IgM. We previously demonstrated that purified human plasma-derived IgA and IgM can be associated with secretory component to generate biologically active secretory-like IgA and IgM (SCIgA/M) that can protect epithelial cells from infection by Shigella flexneri in vitro. In this study, we aimed at evaluating the protective potential of these antibody preparations in vivo. We now establish that such polyreactive preparations bind efficiently to Salmonella enterica Typhimurium and trigger bacterial agglutination, as observed by laser scanning confocal microscopy. Upon delivery into a mouse ligated intestinal loop, SCIgA/M-mediated aggregates persist in the intestinal environment and limit the entry of bacteria into intestinal Peyer's patches via immune exclusion. Moreover, oral administration to mice of immune complexes composed of S. Typhimurium and SCIgA/M reduces mucosal infection, systemic dissemination, and local inflammation. Altogether, our data provide valuable clues for the future appraisal of passive oral administration of polyreactive plasma-derived SCIgA/M to combat infection by a variety of enteropathogens.

9.
Biomaterials ; 142: 41-51, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28727997

RESUMEN

Despite proven efficiency, subcutaneous immunotherapy for aeroallergens is impaired by the duration of the protocol, the repeated injections and potential side-effects associated with the doses of allergen administered. Intranasal delivery of immunotherapeutic agents may overcome several of these drawbacks, provided that an efficient allergen delivery vehicle can be identified. This study evaluates whether intranasally delivered gas-filled microbubble (MB)-associated ovalbumin (OVA), used as a model allergen, can serve as a therapeutic treatment in a mouse model of established allergic asthma. Lung and systemic production of pro-tolerogenic markers, including Foxp3+ CD4 T cells, IL-10, and TGF-ß, as well as the Th1-type cytokine IFN-γ, was observed after intranasal immunization with OVA-MB. Post-treatment, aerosol-sensitized mice exhibited the same pattern of markers. Moreover, decrease of eosinophils and neutrophils in BALs, lower frequencies of Th2 cytokine- and IL-17-producing CD4 T cells in lungs and reduced specific IgE in BALs and sera after allergen challenge were observed. Concomitantly, lung resistance and mucus production diminished in OVA-MB-treated animals. Thus, therapeutic intranasal administration of OVA-MBs in established experimental allergic asthma allows modulating pathology-associated immune and physiological parameters usually triggered after exposure to the allergen.


Asunto(s)
Alérgenos/inmunología , Asma/inmunología , Asma/terapia , Microburbujas/uso terapéutico , Adyuvantes Inmunológicos/farmacología , Administración Intranasal , Animales , Formación de Anticuerpos/efectos de los fármacos , Asma/patología , Modelos Animales de Enfermedad , Femenino , Inmunización , Inmunoglobulina A/inmunología , Inmunoglobulina E/inmunología , Inmunomodulación/efectos de los fármacos , Ratones Endogámicos BALB C , Moco/metabolismo , Ovalbúmina/inmunología , Neumonía/complicaciones , Neumonía/inmunología , Neumonía/patología , Células Th2/efectos de los fármacos , Células Th2/inmunología
10.
J Mol Biol ; 429(15): 2387-2400, 2017 07 21.
Artículo en Inglés | MEDLINE | ID: mdl-28587925

RESUMEN

In addition to contributing to immune exclusion at mucosal surfaces, secretory IgA (SIgA) made of polymeric IgA and secretory component is able to selectively reenter via microfold cells into Peyer's patches (PPs) present along the intestine and to associate with dendritic cells (DCs) of the CD11c+CD11b+MHCII+F4/80-CD8-phenotype in the subepithelial dome region and the draining mesenteric lymph nodes (MLNs). However, the nature of the receptor(s) for SIgA on murine PP and MLN DCs is unknown. We find that glycosylated secretory component moiety and polymeric IgA are both involved in the specific interaction with these cells. Using blocking antibodies and competition experiments, we identify Dectin-1 and specific intercellular adhesion molecule-3 grabbing non-integrin receptor 3 (SIGNR3) as receptors for SIgA. While SIgA-commensal immune complexes (ICs) contribute to local homeostasis upon interaction with mucosal DCs, the picture is less clear for pathogenic agents. We find that in comparison with incubation of Shigella flexneri alone, association of the enteropathogen with SIgA prompts freshly isolated DCs from PPs and MLNs to invert the production of pro- versus non-inflammatory cytokines/chemokines. The sum of the data suggests that in contrast to IgG-based ICs boosting immune reactivity of antigen-presenting cells, SIgA produced during an ongoing immune response can, in addition to its known function of immune exclusion, modulate mucosal DC conditioning via specific interaction with Dectin-1 and SIGNR3.


Asunto(s)
Complejo Antígeno-Anticuerpo/metabolismo , Antígenos CD/metabolismo , Células Dendríticas/inmunología , Inmunoglobulina A Secretora/metabolismo , Lectinas Tipo C/metabolismo , Shigella flexneri/inmunología , Animales , Anticuerpos Antibacterianos/metabolismo , Antígenos Bacterianos/metabolismo , Citocinas/metabolismo , Ganglios Linfáticos/inmunología , Ratones , Ganglios Linfáticos Agregados/inmunología
11.
Microbiol Mol Biol Rev ; 81(3)2017 09.
Artículo en Inglés | MEDLINE | ID: mdl-28615285

RESUMEN

Salmonella enterica subspecies enterica includes several serovars infecting both humans and other animals and leading to typhoid fever or gastroenteritis. The high prevalence of associated morbidity and mortality, together with an increased emergence of multidrug-resistant strains, is a current global health issue that has prompted the development of vaccination strategies that confer protection against most serovars. Currently available systemic vaccine approaches have major limitations, including a reduced effectiveness in young children and a lack of cross-protection among different strains. Having studied host-pathogen interactions, microbiologists and immunologists argue in favor of topical gastrointestinal administration for improvement in vaccine efficacy. Here, recent advances in this field are summarized, including mechanisms of bacterial uptake at the intestinal epithelium, the assessment of protective host immunity, and improved animal models that closely mimic infection in humans. The pros and cons of existing vaccines are presented, along with recent progress made with novel formulations. Finally, new candidate antigens and their relevance in the refined design of anti-Salmonella vaccines are discussed, along with antigen vectorization strategies such as nanoparticles or secretory immunoglobulins, with a focus on potentiating mucosal vaccine efficacy.


Asunto(s)
Inmunidad Mucosa , Mucosa Intestinal/inmunología , Infecciones por Salmonella/prevención & control , Vacunas contra la Salmonella/inmunología , Salmonella/inmunología , Vacunación/métodos , Administración a través de la Mucosa , Animales , Anticuerpos Antibacterianos/inmunología , Interacciones Huésped-Patógeno , Humanos , Inmunoglobulina A Secretora/inmunología , Inmunoglobulina M/inmunología , Mucosa Intestinal/microbiología , Nanopartículas , Infecciones por Salmonella/inmunología , Vacunas contra la Salmonella/administración & dosificación , Fiebre Tifoidea/prevención & control
12.
Gut Microbes ; 8(5): 511-519, 2017 09 03.
Artículo en Inglés | MEDLINE | ID: mdl-28541767

RESUMEN

Despite important success in protecting individuals against many pathogenic infections, parenteral vaccination is not optimal to induce immunity at the site of pathogen entry, i.e. mucosal surfaces. Moreover, designing adequate delivery systems and safe adjuvants to overcome the inherent tolerogenic environment of the mucosal tissue is challenging, in particular in the gastrointestinal tract prone to antigen degradation. We recently demonstrated that intranasal administration of a Salmonella-derived antigen associated with gas-filled microbubbles induced specific Ab and T cell responses in the gut and was associated with a reduction in local and systemic bacterial load after oral Salmonella infection. Building on these promising data, the adequate choice of antigen(s) to be administered and how to make it suitable for possible human application are discussed. We additionally present novel data dealing with oral administration of microbubbles and describe research strategies to direct them to mucosal sampling/inductive sites.


Asunto(s)
Antígenos Bacterianos/administración & dosificación , Antígenos Bacterianos/inmunología , Portadores de Fármacos/administración & dosificación , Sistemas de Liberación de Medicamentos , Tracto Gastrointestinal/inmunología , Microburbujas , Salmonelosis Animal/prevención & control , Administración a través de la Mucosa , Animales , Anticuerpos Antibacterianos/análisis , Carga Bacteriana , Inmunidad Mucosa , Ratones , Salmonella/aislamiento & purificación , Salmonelosis Animal/inmunología , Linfocitos T/inmunología
13.
Cell Mol Immunol ; 14(6): 546-556, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-26972771

RESUMEN

The importance of secretory IgA in controlling the microbiota is well known, yet how the antibody affects the perception of the commensals by the local immune system is still poorly defined. We have previously shown that the transport of secretory IgA in complex with bacteria across intestinal microfold cells results in an association with dendritic cells in Peyer's patches. However, the consequences of such an interaction on dendritic cell conditioning have not been elucidated. In this study, we analyzed the impact of the commensal Lactobacillus rhamnosus, alone or associated with secretory IgA, on the responsiveness of dendritic cells freshly recovered from mouse Peyer's patches, mesenteric lymph nodes, and spleen. Lactobacillus rhamnosus-conditioned mucosal dendritic cells are characterized by increased expression of Toll-like receptor regulatory proteins [including single immunoglobulin interleukin-1 receptor-related molecule, suppressor of cytokine signaling 1, and Toll-interacting molecule] and retinaldehyde dehydrogenase 2, low surface expression of co-stimulatory markers, high anti- versus pro-inflammatory cytokine production ratios, and induction of T regulatory cells with suppressive function. Association with secretory IgA enhanced the anti-inflammatory/regulatory Lactobacillus rhamnosus-induced conditioning of mucosal dendritic cells, particularly in Peyer's patches. At the systemic level, activation of splenic dendritic cells exposed to Lactobacillus rhamnosus was partially dampened upon association with secretory IgA. These data suggest that secretory IgA, through coating of commensal bacteria, contributes to the conditioning of mucosal dendritic cells toward tolerogenic profiles essential for the maintenance of intestinal homeostasis.


Asunto(s)
Células Dendríticas/inmunología , Inmunoglobulina A Secretora/metabolismo , Lacticaseibacillus rhamnosus/fisiología , Membrana Mucosa/inmunología , Linfocitos T Reguladores/inmunología , Familia de Aldehído Deshidrogenasa 1 , Animales , Diferenciación Celular , Células Cultivadas , Células Dendríticas/microbiología , Femenino , Tolerancia Inmunológica , Interleucina-10/metabolismo , Activación de Linfocitos , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Retinal-Deshidrogenasa/metabolismo , Receptores Toll-Like/metabolismo , Factor de Crecimiento Transformador beta/metabolismo
14.
Int J Pharm ; 514(1): 176-188, 2016 Nov 30.
Artículo en Inglés | MEDLINE | ID: mdl-27863662

RESUMEN

Biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres are potential vehicles to deliver antigens for vaccination. Because they lack the full capacity to activate professional antigen presenting cells (APCs), combination with an immunostimulatory adjuvant may be considered. A candidate is the synthetic TLR3 ligand polyriboinosinic acid-polyribocytidylic acid, poly(I:C), which drives cell-mediated immunity. However, poly(I:C) has also been linked to the pathogenesis of autoimmunity, as affected by widespread stimulation of non-hematopoietic bystander cells. To address this aspect, we propose to minimize the poly(I:C) dose as well as to control the stimulation of non-immune bystander cells by poly(I:C). To facilitate the maturation of APCs with minimal poly(I:C) doses, we surface-assembled poly(I:C) onto PLGA microspheres. The microspheres' surface was further modified by poly(ethylene glycol) (PEG) coronas with varying PEG-densities. PLGA microspheres loaded with tetanus toxoid (tt) as model antigen were manufactured by microextrusion-based solvent extraction. The negatively charged PLGA(tt) microspheres were coated with polycationic poly(l-lysine) (PLL) polymers, either PLL itself or PEG-grafted PLL (PLL-g-PEG) with varying grafting ratios (g=2.2 and g=10.1). Stable surface assembly of poly(I:C) was achieved by subsequent incubation of polymer-coated PLGA microspheres with aqueous poly(I:C) solutions. We evaluated the immunostimulatory potential of such PLGA(tt) microsphere formulations on monocyte-derived dendritic cells (MoDCs) as well as human foreskin fibroblasts (HFFs) as model for non-hematopoietic bystander cells. Formulations with surface-assembled poly(I:C) readily activated MoDCs with respect to the expression of maturation-related surface markers, proinflammatory cytokine secretion and directed migration. When surface-assembled, poly(I:C) enhanced its immunostimulatory activity by more than one order of magnitude as compared to free poly(I:C). On fibroblasts, surface-assembled poly(I:C) upregulated class I MHC but not class II MHC. Phagocytosis of PLGA(tt) microsphere formulations by MoDCs and HFFs remained mostly unaffected by PEG-grafted PLL coatings. In contrast, high concentrations of free poly(I:C) led to a marked drop of microsphere phagocytosis by HFFs. Overall, surface assembly on PEGylated PLGA microspheres holds promise to improve both efficacy and safety of poly(I:C) as vaccine adjuvant.


Asunto(s)
Adyuvantes Inmunológicos/química , Antígenos/química , Ácido Láctico/química , Poli I-C/química , Polietilenglicoles/química , Ácido Poliglicólico/química , Polilisina/análogos & derivados , Vacunas/química , Adyuvantes Inmunológicos/farmacología , Antígenos/inmunología , Células Cultivadas , Células Dendríticas/inmunología , Fibroblastos/inmunología , Humanos , Inmunidad Celular/inmunología , Microesferas , Monocitos/inmunología , Fagocitosis/inmunología , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Polilisina/química , Propiedades de Superficie , Toxoide Tetánico/química , Toxoide Tetánico/inmunología , Vacunas/inmunología
15.
J Infect Dis ; 214(3): 438-46, 2016 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-27122591

RESUMEN

Salmonella infection is an increasingly important public health problem owing to the emergence of multidrug resistance and the lack of broadly efficient vaccines. Novel strategies of vaccination are required to induce protective immune responses at mucosal surfaces and in the circulation, to limit bacteria entry and dissemination. To this aim, intranasal anti-Salmonella vaccination with an innovative formulation composed of gas-filled microbubbles and the pathogen-derived protective protein serodominant secreted effector protein B (SseB-MB) was evaluated in a mouse infection model. Intranasal application of SseB-MB induced gut and systemic immunoglobulin A, T-helper type 17 cell (Th17), and Th1 responses, all of which are associated with natural immunity against Salmonella In vaccinated mice, a significant reduction in bacterial load was observed in intestinal tissues and the spleen after an otherwise lethal oral infection. Therefore, MB serve as an efficient carrier for nasal delivery of a Salmonella antigen that results in protection upon activation of the common mucosal immune system.


Asunto(s)
Antígenos Bacterianos/inmunología , Proteínas Bacterianas/inmunología , Portadores de Fármacos/administración & dosificación , Tracto Gastrointestinal/inmunología , Chaperonas Moleculares/inmunología , Infecciones por Salmonella/prevención & control , Vacunas contra la Salmonella/inmunología , Salmonella/inmunología , Administración Intranasal , Animales , Anticuerpos Antibacterianos/análisis , Anticuerpos Antibacterianos/sangre , Antígenos Bacterianos/administración & dosificación , Carga Bacteriana , Proteínas Bacterianas/administración & dosificación , Modelos Animales de Enfermedad , Femenino , Tracto Gastrointestinal/microbiología , Inmunidad Mucosa , Inmunoglobulina A/análisis , Inmunoglobulina A/sangre , Ratones Endogámicos BALB C , Chaperonas Moleculares/administración & dosificación , Infecciones por Salmonella/inmunología , Vacunas contra la Salmonella/administración & dosificación , Células TH1/inmunología , Células Th17/inmunología , Resultado del Tratamiento
16.
J Allergy Clin Immunol ; 137(1): 214-222.e2, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26414879

RESUMEN

BACKGROUND: Transmission of mucosal pathogens relies on their ability to bind to the surfaces of epithelial cells, to cross this thin barrier, and to gain access to target cells and tissues, leading to systemic infection. This implies that pathogen-specific immunity at mucosal sites is critical for the control of infectious agents using these routes to enter the body. Although mucosal delivery would ensure the best onset of protective immunity, most of the candidate vaccines are administered through the parenteral route. OBJECTIVE: The present study evaluates the feasibility of delivering the chemically bound p24gag (referred to as p24 in the text) HIV antigen through secretory IgA (SIgA) in nasal mucosae in mice. RESULTS: We show that SIgA interacts specifically with mucosal microfold cells present in the nasal-associated lymphoid tissue. p24-SIgA complexes are quickly taken up in the nasal cavity and selectively engulfed by mucosal dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin-positive dendritic cells. Nasal immunization with p24-SIgA elicits both a strong humoral and cellular immune response against p24 at the systemic and mucosal levels. This ensures effective protection against intranasal challenge with recombinant vaccinia virus encoding p24. CONCLUSION: This study represents the first example that underscores the remarkable potential of SIgA to serve as a carrier for a protein antigen in a mucosal vaccine approach targeting the nasal environment.


Asunto(s)
Proteína p24 del Núcleo del VIH/inmunología , Inmunización/métodos , Inmunoglobulina A Secretora/inmunología , Tejido Linfoide/inmunología , Mucosa Nasal/inmunología , Administración Intranasal , Animales , Citocinas/inmunología , Células Dendríticas , Femenino , Inmunidad Mucosa , Inmunoglobulina A/inmunología , Inmunoglobulina G/inmunología , Tejido Linfoide/citología , Ratones Endogámicos BALB C , Ratones Noqueados , Mucosa Nasal/citología , Bazo/inmunología , Vagina/inmunología
17.
Biomaterials ; 57: 153-60, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25916503

RESUMEN

Vaccination aims at generating memory immune responses able to protect individuals against pathogenic challenges over long periods of time. Subunit vaccine formulations based on safe, but poorly immunogenic, antigenic entities must be combined with adjuvant molecules to make them efficient against infections. We have previously shown that gas-filled microbubbles (MB) are potent antigen-delivery systems. This study compares the ability of various ovalbumin-associated MB (OVA-MB) formulations to induce antigen-specific memory immune responses and evaluates long-term protection toward bacterial infections. When initially testing dendritic cells reactivity to MB constituents, palmitic acid exhibited the highest degree of activation. Subcutaneous immunization of naïve wild-type mice with the OVA-MB formulation comprising the highest palmitic acid content and devoid of PEG2000 was found to trigger the more pronounced Th1-type response, as reflected by robust IFN-γ and IL-2 production. Both T cell and antibody responses persisted for at least 6 months after immunization. At that time, systemic infection with OVA-expressing Listeria monocytgenes was performed. Partial protection of vaccinated mice was demonstrated by reduction of the bacterial load in both the spleen and liver. We conclude that antigen-bound MB exhibit promising properties as a vaccine candidate ensuring prolonged maintenance of protective immunity.


Asunto(s)
Vacunas Bacterianas/administración & dosificación , Vacunas Bacterianas/uso terapéutico , Infecciones por Bacterias Grampositivas/prevención & control , Listeria/inmunología , Microburbujas , Ovalbúmina/administración & dosificación , Ovalbúmina/uso terapéutico , Animales , Vacunas Bacterianas/genética , Vacunas Bacterianas/inmunología , Femenino , Expresión Génica , Infecciones por Bacterias Grampositivas/inmunología , Humanos , Inmunidad , Interferón gamma/inmunología , Interleucina-2/inmunología , Listeria/genética , Ratones , Ratones Endogámicos BALB C , Ovalbúmina/genética , Ovalbúmina/inmunología , Recombinación Genética , Vacunación
18.
Eur J Immunol ; 45(3): 773-9, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25412898

RESUMEN

HIV transmission and spread in the host are based on the survival of the virus or infected cells present in mucosal secretions, and the virus' ability to cross the epithelial barrier and access immune target cells, which leads to systemic infection. Therefore, HIV-specific immunity at mucosal sites is critical for control of infection. Although mucosal delivery would ensure the best onset of protective immunity, most candidate vaccines are administered through the parenteral route. Remarkably, secretory IgA (SIgA) interacts specifically with mucosal microfold (M) cells present in gut-associated lymphoid tissues. Here we evaluate the feasibility of delivering chemically bound p24HIV antigen via SIgA into the intestinal mucosae in mice. After oral administration, p24-SIgA complexes are quickly delivered into the tissue and selectively captured by CX3CR1(+) dendritic cells. Oral immunization with p24gag linked to SIgA (p24-SIgA) adjuvanted with E. coli heat labile enterotoxin (HLT) elicits both humoral and cellular immune responses against p24 at the systemic and mucosal levels and induces efficient protection against rectal challenge with a recombinant vaccinia virus encoding gag. This is the first study which underscores the remarkable potential of SIgA to serve as a vaccine carrier for an HIV antigen in mucosal administration targeting the gastrointestinal environment.


Asunto(s)
Vacunas contra el SIDA/farmacología , Portadores de Fármacos/farmacología , Proteína p24 del Núcleo del VIH/farmacología , VIH-1/inmunología , Inmunoglobulina A Secretora/farmacología , Mucosa Intestinal/inmunología , Vacunas contra el SIDA/inmunología , Animales , Proteína p24 del Núcleo del VIH/inmunología , Inmunidad Celular/efectos de los fármacos , Inmunidad Humoral/efectos de los fármacos , Inmunoglobulina A Secretora/inmunología , Ratones , Ratones Endogámicos BALB C , Ratones Transgénicos
19.
Gut Microbes ; 5(6): 688-95, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25536286

RESUMEN

While the gut epithelium represents the largest mucosal tissue, the mechanisms underlying the interaction between intestinal bacteria and the host epithelium lead to multiple outcomes that remain poorly understood at the molecular level. Deciphering such events may provide valuable information as to the mode of action of commensal and probiotic microorganisms in the gastrointestinal environment. Potential roles of such microorganisms along the privileged target represented by the intestinal immune system include maturation processes prior, during and after weaning, and the reduction of inflammatory reactions in pathogenic conditions. As commensal bacteria are naturally coated by natural and antigen-specific SIgA in the gut lumen, understanding the consequences of such an interaction may provide new clues on how the antibody contributes to homeostasis at mucosal surfaces. This review discusses several aspects of the role of SIgA in the essential communication existing between the host epithelium and members of its microbiota.


Asunto(s)
Fenómenos Fisiológicos Bacterianos , Inmunoglobulina A Secretora/inmunología , Mucosa Intestinal/microbiología , Simbiosis , Animales , Bacterias/inmunología , Humanos , Mucosa Intestinal/inmunología
20.
J Biol Chem ; 289(31): 21617-26, 2014 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-24951593

RESUMEN

Intravenous administration of polyclonal and monoclonal antibodies has proven to be a clinically valid approach in the treatment, or at least relief, of many acute and chronic pathologies, such as infection, immunodeficiency, and a broad range of autoimmune conditions. Plasma-derived IgG or recombinant IgG are most frequently used for intravenous or subcutaneous administration, whereas a few IgM-based products are available as well. We have established recently that secretory-like IgA and IgM can be produced upon association of plasma-derived polymeric IgA and IgM with a recombinant secretory component. As a next step toward potential future mucosal administration, we sought to unravel the mechanisms by which these secretory Igs protect epithelial cells located at the interface between the environment and the inside of the body. By using polarized epithelial Caco-2 cell monolayers and Shigella flexneri as a model enteropathogen, we found that polyspecific plasma-derived SIgA and SIgM fulfill many protective functions, including dose-dependent recognition of the antigen via formation of aggregated immune complexes, reduction of bacterial infectivity, maintenance of epithelial cell integrity, and inhibition of proinflammatory cytokine/chemokine production by epithelial cells. In this in vitro model devoid of other cellular or molecular interfering partners, IgM and secretory IgM showed stronger bacterial neutralization than secretory IgA. Together, these data suggest that mucosally delivered antibody preparations may be most effective when combining both secretory-like IgA and IgM, which, together, play a crucial role in preserving several levels of epithelial cell integrity.


Asunto(s)
Células Epiteliales/citología , Inmunoglobulina A/inmunología , Inmunoglobulina M/inmunología , Shigella flexneri/fisiología , Células CACO-2 , Quimiocinas/metabolismo , Recuento de Colonia Microbiana , Citocinas/metabolismo , Ensayo de Inmunoadsorción Enzimática , Células Epiteliales/metabolismo , Células Epiteliales/microbiología , Homeostasis , Humanos , Inmunoglobulina A/sangre , Inmunoglobulina M/sangre , Microscopía Confocal , Shigella flexneri/patogenicidad , Virulencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...